Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Mivacurium (compound)

Name: mivacurium
PubChem Compound ID: 104803
Molecular formula: C58H80N2O14+2
Molecular weight: 1029.26 g/mol
Name: mivacurium
Name (isomeric): DB01226
Drug Type: small molecule
Brand: Mivacron
Category: Neuromuscular Nondepolarizing Agents
CAS number: 106791-40-6
Indication: For inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Mivacurium is a short-acting, nondepolarizing skeletal neuromuscular blocking agent which is hydrolyzed by plasma cholinesterase. Mivacurium results in a blockade of neuromuscular transmission by binding competitively with cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine. The neuromuscular block produced by miv...
show more »
Mechanism of Action: Mivacurium binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.
Protein binding: The protein binding of mivacurium has not been determined due to its rapid hydrolysis by plasma cholinesterase.
Biotransformation: Extensive and rapid via enzymatic hydrolysis catalyzed by plasma cholinesterase. Biotransformation may be significantly slowed in patients with abnormal or decreased plasma cholinesterase activity, especially individuals with a homozygous atypical cholinesterase gene abnormality.
Half Life: The mean elimination half-life ranges from 1.7 to 2.6 minutes in healthy, young adults administered 0.1 to 0.25 mg/kg mivacurium. In 9 patients with end-stage liver disease undergoing liver transplant surgery, plasma clearance was approximately 50% lower than that in 8 control patients with normal hepatic function, while the elimination half-life increased to 4.4 minutes from the 1.8 minute control value.
Toxicity: Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
Affected organisms: Humans and other mammals
Drug interaction:
TobramycinThe agent increases the effect of the muscle relaxant
AzathioprineThe agent decreases the effect of the muscle relaxant
PhenytoinPhenytoin decreases the effect of the muscle relaxant
AminophyllineTheophylline decreases the effect of muscle relaxant
AmikacinThe agent increases the effect of muscle relaxant
show more »